BD出海又成为了“催化剂”。来源|医药研究社“BD之王”再出手。近日,和铂医药发布公告称,其与大冢制药达成全球战略合作协议,双方将共同推进用于治疗自身免疫性疾病的BCMAxCD3双特异性T细胞衔接器(TCE)的开发。根据协议,大冢制药被授予在全球范围内(不包括大中华区,即中国大陆、香港、台湾及澳门)开发、制造及商业化HBM7020的独家权利。和铂医药将获得总计4700万美元的首付款和近期里程碑付款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.